Drug Trial Radar · NCT04208412
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
Last checked: Nov 19, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Jul 2, 2019
Primary completion
Dec 8, 2020
Study completion Dec 8, 2020
Sponsor
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adult subjects.
Conditions
- Hereditary Angioedema
Interventions
KVD900Drug
KVD900 tablet 600 mg
PlaceboOther
KVD900-matched Placebo Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Conventional Attack Treatment Use Within 12 Hours of Study Drug (Full Analysis Set)Time frame: 12 hours
Locations
25 sites in 10 countries. Site status is shown where the registry gives one.
KalVista Investigative Site
Scottsdale, Arizona
KalVista Investigative Site
Centennial, Colorado
KalVista Investigative Site
Chevy Chase, Maryland
KalVista Investigative Site
Cincinnati, Ohio
KalVista Investigative Site
Dallas, Texas
KalVista Investigative Site
Spokane, Washington
KalVista Investigative Site
Vienna, Austria
KalVista Investigative Site
Brno, Czechia
KalVista Investigative Site
Hradec Králové, Czechia
KalVista Investigative Site
Pilsen, Czechia
KalVista Investigative Site
Berlin, Germany
KalVista Investigative Site
Frankfurt, Germany
KalVista Investigative Site
Mörfelden-Walldorf, Germany
KalVista Investigative Site
Budapest, Hungary
KalVista Investigative Site
Milan, Italy
KalVista Investigative Site
Milano-2, Italy
KalVista Investigative Site
Padova, Italy
KalVista Investigative Site
Amsterdam, Netherlands
KalVista Investigative Site
Skopje, North Macedonia
KalVista Investigative Site
Krakow, Poland
KalVista Investigative Site
Warsaw, Poland
KalVista Investigative Site
Camberley, United Kingdom
KalVista Investigative Site
Cambridge, United Kingdom
KalVista Investigative Site
London, United Kingdom
KalVista Investigative Site
Newcastle, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.